Design, development, and formulation of Glipizide fast-dissolving tablets

Abstract

Fast-dissolving tablets (FDTs) are designed to disintegrate rapidly in the oral cavity, offering improved patient compliance and faster onset of action compared to conventional oral solid dosage forms. The present study was undertaken to design, develop, and evaluate fast-dissolving tablets of Glipizide, a second-generation sulfonylurea used in the management of Type-2 Diabetes Mellitus. Glipizide fast-dissolving tablets were formulated by the direct compression method using different superdisintegrants, namely crospovidone, croscarmellose sodium, and sodium starch glycolate, at varying concentrations. Preformulation studies were conducted to assess the physicochemical properties of the drug, and drug–excipient compatibility was evaluated using FTIR spectroscopy. The prepared formulations were evaluated for pre-compression parameters, post-compression characteristics, wetting time, disintegration time, drug content, and in-vitro dissolution behavior. Among the ten formulations developed, formulation F10 containing a combination of crospovidone and croscarmellose sodium exhibited the shortest disintegration time, rapid wetting, and nearly complete drug release within a short duration. Accelerated stability studies carried out as per ICH guidelines confirmed the physical and chemical stability of the optimized formulation. The study concludes that Glipizide fast-dissolving tablets prepared by direct compression represent a promising, patient-friendly alternative to conventional tablets, with potential benefits in terms of rapid onset of action and improved therapeutic compliance.